Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T16691 | ||||
Target Name | 5-HT 6 receptor (HTR6) | ||||
Type of Target |
Clinical trial |
||||
Drug Potency against Target | SB-742457 | Drug Info | Ki = 0.25 nM | [30] | |
Drug Info | Ki = 400 nM | [1] | |||
(+/-)-nantenine | Drug Info | Ki = 257 nM | [25] | ||
1-(2-Methoxy-phenyl)-piperazine | Drug Info | Ki = 1.2 nM | [5] | ||
1-(3-(benzyloxy)-2-methylphenyl)piperazine | Drug Info | Ki = 1.3 nM | [21] | ||
1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole | Drug Info | Ki = 1 nM | [10] | ||
1-Benzenesulfonyl-3-piperidin-3-yl-1H-indole | Drug Info | Ki = 1 nM | [9] | ||
1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole | Drug Info | IC50 = 19.5 nM | [3] | ||
1-naphthylpiperazine | Drug Info | Ki = 100 nM | [5] | ||
1-phenylthio-N,N-dimethyltryptamine | Drug Info | Ki = 90 nM | [18] | ||
2-(1-(phenylsulfonyl)-1H-indol-3-yl)ethanamine | Drug Info | Ki = 10 nM | [15] | ||
2-(1-benzyl-1H-inden-3-yl)-N,N-dimethylethanamine | Drug Info | Ki = 3 nM | [20] | ||
2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine | Drug Info | Ki = 6 nM | [20] | ||
2-(1-tosyl-1H-indol-3-yl)ethanamine | Drug Info | Ki = 8 nM | [15] | ||
2-(3-(phenylsulfonyl)-1H-indol-1-yl)ethanamine | Drug Info | Ki = 25 nM | [22] | ||
2-(3-benzenesulfonyl)phenyl-1-aminoethane | Drug Info | Ki = 50 nM | [12] | ||
2-(3-phenylthio)phenyl)-1-aminoethane | Drug Info | Ki = 115 nM | [12] | ||
2-(4-(benzenesulfonyl)phenyl)-1-aminoethane | Drug Info | Ki = 37 nM | [12] | ||
2-Benzyl-4-piperazin-1-yl-1H-benzimidazole | Drug Info | Ki = 31 nM | [26] | ||
2-Ethyl-5-methoxy-3-piperidin-4-yl-1H-indole | Drug Info | IC50 = 300 nM | [8] | ||
3-(phenylsulfonyl)-1-(piperidin-3-yl)-1H-indole | Drug Info | Ki = 13 nM | [27] | ||
3-(phenylsulfonyl)-1-(piperidin-4-yl)-1H-indole | Drug Info | Ki = 91 nM | [27] | ||
3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1H-indole | Drug Info | Ki = 5 nM | [27] | ||
4-((1H-indol-1-yl)methyl)benzenamine | Drug Info | Ki = 8200 nM | [14] | ||
4-(1H-Inden-1-ylmethyl)-phenylamine | Drug Info | Ki = 4470 nM | [7] | ||
4-(1H-indol-1-ylsulfonyl)benzenamine | Drug Info | Ki = 10 nM | [10] | ||
4-(1H-Indol-3-ylmethyl)-phenylamine | Drug Info | Ki = 2530 nM | [7] | ||
4-(2-benzenesulfonylphenyl)piperazine | Drug Info | Ki = 4000 nM | [12] | ||
4-(3-benzenesulfonamidophenyl)piperazine | Drug Info | Ki = 62 nM | [12] | ||
4-(3-benzenesulfonylphenyl)piperazine | Drug Info | Ki = 1.2 nM | [12] | ||
4-(3-Methyl-indole-1-sulfonyl)-phenylamine | Drug Info | Ki = 12 nM | [5] | ||
4-(3H-Inden-1-ylmethyl)-phenylamine | Drug Info | Ki = 11800 nM | [7] | ||
4-(4,6-dinitro-1H-indol-1-ylsulfonyl)benzenamine | Drug Info | Ki = 980 nM | [10] | ||
4-(4-benzenesulfonamidophenyl)piperazine | Drug Info | Ki = 85 nM | [12] | ||
4-(4-benzenesulfonylphenyl)piperazine | Drug Info | Ki = 6.9 nM | [12] | ||
4-(4-methoxy-1H-indol-1-ylsulfonyl)benzenamine | Drug Info | Ki = 3.3 nM | [11] | ||
4-(6-methoxy-1H-indol-1-ylsulfonyl)benzenamine | Drug Info | Ki = 1.8 nM | [11] | ||
4-(Indan-1-ylsulfanyl)-phenylamine | Drug Info | Ki = 4200 nM | [7] | ||
4-(Indane-1-sulfonyl)-phenylamine | Drug Info | Ki = 740 nM | [7] | ||
4-(Naphthalene-1-sulfonyl)-phenylamine | Drug Info | Ki = 34 nM | [5] | ||
4-(piperazin-1-yl)-1H-indole | Drug Info | Ki = 2700 nM | [10] | ||
4-(piperazin-1-yl)-3-tosyl-1H-indazole | Drug Info | Ki = 134 nM | [29] | ||
4-Indan-1-ylmethyl-phenylamine | Drug Info | Ki = 6100 nM | [7] | ||
4-Inden-(1E)-ylidenemethyl-phenylamine | Drug Info | Ki = 640 nM | [7] | ||
5,6-dichloro-3,4-dihydroquinazolin-2-amine | Drug Info | Ki = 1157 nM | [16] | ||
5-(4-Methylpiperazin-1-yl)-3-tosyl-1H-indazole | Drug Info | IC50 = 112 nM | [29] | ||
5-MEO-DMT | Drug Info | Ki = 13 nM | [13] | ||
5-METHOXYTRYPTAMINE | Drug Info | Ki < 50 nM | [6] | ||
6-(piperazin-1-yl)-3-tosyl-1H-indazole | Drug Info | Ki = 27 nM | [29] | ||
6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole | Drug Info | Ki = 29 nM | [19] | ||
CHLOROPHENYLPIPERAZINE | Drug Info | Ki = 2300 nM | [1] | ||
DIMEBOLIN | Drug Info | Ki = 26 nM | [24] | ||
E-6837 | Drug Info | Ki = 0.7 nM | [20] | ||
EDMT | Drug Info | Ki = 16 nM | [20] | ||
METHIOTHEPIN | Drug Info | IC50 = 2.4 nM | [28] | ||
N,N-diethyl-2-(1H-indol-3-yl)ethanamine | Drug Info | Ki = 575 nM | [13] | ||
N,N-dimethyl-2-(1-tosyl-1H-indol-3-yl)ethanamine | Drug Info | Ki = 2.5 nM | [14] | ||
N-(3-(2-aminoethyl)phenyl)benzenesulfonamide | Drug Info | Ki = 21 nM | [12] | ||
N-(3-(3-aminopropyl)phenyl)benzenesulfonamide | Drug Info | Ki = 230 nM | [12] | ||
N-(3-(aminomethyl)phenyl)benzenesulfonamide | Drug Info | Ki = 290 nM | [12] | ||
N-(3-aminophenyl)benzenesulfonamide | Drug Info | Ki = 2840 nM | [12] | ||
N-(4-(2-aminoethyl)phenyl)benzenesulfonamide | Drug Info | Ki = 38 nM | [12] | ||
N-phenyl-3-(2-aminoethyl)benzenesulfonamide | Drug Info | Ki = 70 nM | [12] | ||
OCTOCLOTHEPIN | Drug Info | Ki < 50 nM | [6] | ||
QUIPAZINE | Drug Info | Ki = 3600 nM | [1] | ||
Ro-04-6790 | Drug Info | Ki = 47 nM | [20] | ||
SB-271046 | Drug Info | Ki = 0.66 nM | [21] | ||
SB-357134 | Drug Info | Ki = 3 nM | [17] | ||
SEROTONIN | Drug Info | IC50 = 27.5 nM | [28] | ||
WAY-181187 | Drug Info | Ki = 2 nM | [23] | ||
WAY-208466 | Drug Info | Ki = 4.8 nM | [22] | ||
WAY-466 | Drug Info | Ki = 1 nM | [4] | ||
[2-(3-Benzyl-3H-inden-1-yl)-ethyl]-methyl-amine | Drug Info | Ki = 3 nM | [7] | ||
[2-(3-Benzyl-3H-indol-1-yl)-ethyl]-dimethyl-amine | Drug Info | Ki = 6 nM | [2] | ||
[2-(3-Benzyl-indol-1-yl)-ethyl]-dimethyl-amine | Drug Info | Ki = 32 nM | [7] | ||
[2-(3H-Indol-1-yl)-ethyl]-dimethyl-amine | Drug Info | Ki = 1900 nM | [2] | ||
[3H]Ro 63-0563 | Drug Info | Ki = 512 nM | [17] | ||
[3H]spiperone | Drug Info | Ki = 1595 nM | [1] | ||
Action against Disease Model | SB-742457 | Drug Info | The effect of a selective 5-HT(6) receptor antagonist SB-742457 to reverse sub-chronic phencyclidine (PCP)-induced cognitive deficits in female rats was examined. The PCP-induced selective reversal learning deficit was significantly improved by SB-742457. | [31] | |
References | |||||
REF 1 | Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. | ||||
REF 2 | Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4569-73. | ||||
REF 3 | N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2005 Jan 17;15(2):379-83. | ||||
REF 4 | Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6. | ||||
REF 5 | 1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1707-11. | ||||
REF 6 | Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J Med Chem. 2005 Mar 24;48(6):1781-95. | ||||
REF 7 | Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91. | ||||
REF 8 | 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4230-4. | ||||
REF 9 | Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4780-5. | ||||
REF 10 | Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5298-302. | ||||
REF 11 | Binding of methoxy-substituted N1-benzenesulfonylindole analogs at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3793-6. | ||||
REF 12 | Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. | ||||
REF 13 | Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5832-5. | ||||
REF 14 | Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1691-4. | ||||
REF 15 | Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist. J Med Chem. 2007 Nov 15;50(23):5535-8. | ||||
REF 16 | Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. | ||||
REF 17 | Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. | ||||
REF 18 | Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies. J Med Chem. 2008 Feb 14;51(3):603-11. | ||||
REF 19 | A regiospecific synthesis of a series of 1-sulfonyl azepinoindoles as potent 5-HT6 ligands. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3929-31. | ||||
REF 20 | Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87. | ||||
REF 21 | Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg Med Chem Lett. 2009 May 1;19(9):2409-12. | ||||
REF 22 | Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. | ||||
REF 23 | Identification of novel indanylsulfonamide guanylhydrazones as potent 5-HT6 serotonin receptor antagonists. J Med Chem. 2009 Oct 8;52(19):6153-7. | ||||
REF 24 | 8-Sulfonyl-substituted tetrahydro-1H-pyrido[4,3-b]indoles as 5-HT6 receptor antagonists. Eur J Med Chem. 2010 Feb;45(2):782-9. | ||||
REF 25 | Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. | ||||
REF 26 | Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation. J Med Chem. 2010 Feb 11;53(3):1357-69. | ||||
REF 27 | 3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1657-60. | ||||
REF 28 | 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. J Med Chem. 2010 Mar 25;53(6):2521-7. | ||||
REF 29 | 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists. J Med Chem. 2010 Nov 11;53(21):7639-46. | ||||
REF 30 | 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics. 2008 Jul;5(3):458-69. | ||||
REF 31 | Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl). 2010 Jan;208(1):23-36. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.